Approved,Small molecule,Investigational,Name,Synonyms,InChI,Number of targets,SMILES,Target name,Target gene name,Target actions
TRUE,TRUE,TRUE,Fenfluramine,(±)-fenfluramine; 1-(m-trifluoromethyl-phenyl)-2-ethylaminopropane; DL-Fenfluramine; Fenfluramina; Fenfluramine; Fenfluraminum,"InChI=1S/C12H16F3N/c1-3-16-9(2)7-10-5-4-6-11(8-10)12(13,14)15/h4-6,8-9,16H,3,7H2,1-2H3",7,CCNC(C)CC1=CC=CC(=C1)C(F)(F)F,5-hydroxytryptamine receptor 2C; 5-hydroxytryptamine receptor 2B; Cytochrome P450 2D6; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 2A; Sodium-dependent serotonin transporter; 5-hydroxytryptamine receptor 1D; Sigma non-opioid intracellular receptor 1; 5-hydroxytryptamine receptor 1A; Cytochrome P450 1A2; Cytochrome P450 2B6; Cytochrome P450 2C9; Cytochrome P450 2C19; Cytochrome P450 3A4; Cytochrome P450 3A5,HTR2C; HTR2B; CYP2D6; SLC6A4; HTR2A; HTR1D; SIGMAR1; HTR1A; CYP1A2; CYP2B6; CYP2C9; CYP2C19; CYP3A4; CYP3A5,agonist; substrate; inhibitor; antagonist
TRUE,TRUE,TRUE,Sulfamethizole,Sulfamethizol; Sulfaméthizol; Sulfamethizole; Sulfamethizolum; Sulfamethylthiadiazole; Sulfametizol,"InChI=1S/C9H10N4O2S2/c1-6-11-12-9(16-6)13-17(14,15)8-4-2-7(10)3-5-8/h2-5H,10H2,1H3,(H,12,13)",1,CC1=NN=C(NS(=O)(=O)C2=CC=C(N)C=C2)S1,Dihydropteroate synthase; Serum albumin; Cytochrome P450 2C9,folP; ALB; CYP2C9,inhibitor
TRUE,TRUE,TRUE,Lisuride,"Lisurid; Lisurida; Lisuride; Lisuridum; N'-((8alpha)-9,10-Didehydro-6-methylergolin-8-yl)-N,N-diethylurea","InChI=1S/C20H26N4O/c1-4-24(5-2)20(25)22-14-10-16-15-7-6-8-17-19(15)13(11-21-17)9-18(16)23(3)12-14/h6-8,10-11,14,18,21H,4-5,9,12H2,1-3H3,(H,22,25)/t14-,18+/m0/s1",15,[H][C@@]12CC3=CNC4=CC=CC(=C34)C1=C[C@@H](CN2C)NC(=O)N(CC)CC,Dopamine D1 receptor; 5-hydroxytryptamine receptor 1A; Dopamine D2 receptor; Alpha-2A adrenergic receptor; Alpha-2B adrenergic receptor; Alpha-2C adrenergic receptor; Dopamine D3 receptor; 5-hydroxytryptamine receptor 1D; 5-hydroxytryptamine receptor 2B; 5-hydroxytryptamine receptor 2A; Dopamine D4 receptor; 5-hydroxytryptamine receptor 2C; Dopamine D5 receptor; 5-hydroxytryptamine receptor 1B; Cytochrome P450 3A4; 5-hydroxytryptamine receptor 7,DRD1; HTR1A; DRD2; ADRA2A; ADRA2B; ADRA2C; DRD3; HTR1D; HTR2B; HTR2A; DRD4; HTR2C; DRD5; HTR1B; CYP3A4; HTR7,antagonist; agonist; other/unknown; substrate
TRUE,TRUE,TRUE,Cisapride,Cisaprid; Cisaprida; Cisapride; Cisapridum,"InChI=1S/C23H29ClFN3O4/c1-30-21-13-19(26)18(24)12-17(21)23(29)27-20-8-10-28(14-22(20)31-2)9-3-11-32-16-6-4-15(25)5-7-16/h4-7,12-13,20,22H,3,8-11,14,26H2,1-2H3,(H,27,29)/t20-,22+/m1/s1",4,CO[C@H]1CN(CCCOC2=CC=C(F)C=C2)CC[C@H]1NC(=O)C1=CC(Cl)=C(N)C=C1OC,5-hydroxytryptamine receptor 4; 5-hydroxytryptamine receptor 3A; Potassium voltage-gated channel subfamily H member 2; 5-hydroxytryptamine receptor 2A; Cytochrome P450 3A4; Cytochrome P450 3A5; Cytochrome P450 3A7; Cytochrome P450 2A6; Cytochrome P450 2B6; Cytochrome P450 2C19; Cytochrome P450 2C8; Cytochrome P450 2C9; Cytochrome P450 2D6,HTR4; HTR3A; KCNH2; HTR2A; CYP3A4; CYP3A5; CYP3A7; CYP2A6; CYP2B6; CYP2C19; CYP2C8; CYP2C9; CYP2D6,agonist; inhibitor; substrate
TRUE,TRUE,TRUE,Guanabenz,Guanabenz; Guanabenzo; Guanabenzum,"InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+",2,NC(N)=NN=CC1=C(Cl)C=CC=C1Cl,Alpha-2A adrenergic receptor; Cytochrome P450 1A2; Alpha-2B adrenergic receptor,ADRA2A; CYP1A2; ADRA2B,agonist; substrate; binder
